Nama's AI scorecard currently rates Bausch + Lomb Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BLCO's P/E ratio?

Bausch + Lomb trades at a trailing price-to-earnings ratio of 22.2.

When does BLCO report earnings?

Bausch + Lomb's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $0.37.

What is the BLCO price target?

The median analyst price target from 14 analysts is $22.00, with a range of $18.00 – $26.00.

Is BLCO Shariah compliant?

Nama's AAOIFI-style screen reads Bausch + Lomb as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Bausch + Lomb (BLCO)

Healthcare · Medical Instruments Supplies · NYSE

Bausch + Lomb (BLCO) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $7.15B, a trailing price-to-earnings ratio of 22.2 and a free-cash-flow yield of -0.9%. Over the most recent reported fiscal year, revenue grew 6.5%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +11.7% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-8.9%

How far the last close sits under the highest price of the past five years.

Market cap	$7.15B
Trailing P/E	22.2
Price / book	1.1
Price / sales	1.3
FCF yield	-0.9%
Dividend yield	—
Gross margin	62.5%
Operating margin	9.4%
Net margin	-2.0%
Revenue growth (YoY)	+6.5%
Revenue growth (3-yr annual)	+10.6%
EPS growth (YoY)	-19.4%
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

BLCO earnings

Next report: Feb 17, 2027 (Q4 2026, EPS estimate $0.37). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$0.34	$0.22	+54.5%	$1.38B
Q2 2026	Jul 29, 2026	$0.16	$0.16	+0.0%	$1.39B
Q1 2026	Apr 29, 2026	$0.08	$0.05	+60.0%	$1.24B
Q4 2025	Feb 18, 2026	$0.32	$0.36	-11.1%	$1.41B

BLCO analyst price target

Median target $22.00 from 14 analysts, ranging $18.00 – $26.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live BLCO data on Nama Insights →

BLCO FAQ

Is BLCO a buy?: Nama's AI scorecard currently rates Bausch + Lomb Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BLCO's P/E ratio?: Bausch + Lomb trades at a trailing price-to-earnings ratio of 22.2.
When does BLCO report earnings?: Bausch + Lomb's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $0.37.
What is the BLCO price target?: The median analyst price target from 14 analysts is $22.00, with a range of $18.00 – $26.00.
Is BLCO Shariah compliant?: Nama's AAOIFI-style screen reads Bausch + Lomb as Not Shariah Compliant. At least one of the three ratios or the industry test failed.